779 related articles for article (PubMed ID: 26843176)
1. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
[TBL] [Abstract][Full Text] [Related]
2. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
5. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
6. Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Pitre T; Mah J; Helmeczi W; Khalid MF; Cui S; Zhang M; Husnudinov R; Su J; Banfield L; Guy B; Coyne J; Scallan C; Kolb MR; Jones A; Zeraatkar D
Thorax; 2022 Dec; 77(12):1243-1250. PubMed ID: 35145039
[TBL] [Abstract][Full Text] [Related]
7. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Loveman E; Copley VR; Scott DA; Colquitt JL; Clegg AJ; O'Reilly KM
BMC Pulm Med; 2015 Apr; 15():37. PubMed ID: 25927225
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.
Wu X; Li W; Luo Z; Chen Y
BMC Pulm Med; 2024 Jan; 24(1):58. PubMed ID: 38281037
[TBL] [Abstract][Full Text] [Related]
9. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
Covvey JR; Mancl EE
Ann Pharmacother; 2014 Dec; 48(12):1611-9. PubMed ID: 25202034
[TBL] [Abstract][Full Text] [Related]
10. German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Behr J; Günther A; Bonella F; Geißler K; Koschel D; Kreuter M; Prasse A; Schönfeld N; Sitter H; Müller-Quernheim J; Costabel U
Pneumologie; 2018 Feb; 72(2):155-168. PubMed ID: 29341047
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.
Pang LJ; Liu JP; Lv XD
Medicine (Baltimore); 2019 Jul; 98(30):e16325. PubMed ID: 31348231
[TBL] [Abstract][Full Text] [Related]
12. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
15. Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis.
Scott DA; Loveman E; Colquitt JL; O'Reilly K
Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31390809
[No Abstract] [Full Text] [Related]
16. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.
Loveman E; Copley VR; Colquitt JL; Scott DA; Clegg AJ; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
BMC Pharmacol Toxicol; 2014 Nov; 15():63. PubMed ID: 25410822
[TBL] [Abstract][Full Text] [Related]
17. New treatments in idiopathic pulmonary fibrosis.
Strâmbu I
Pneumologia; 2016; 65(3):127-32. PubMed ID: 29542881
[TBL] [Abstract][Full Text] [Related]
18. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
19. Health economic evaluation in idiopathic pulmonary fibrosis in France.
Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
[TBL] [Abstract][Full Text] [Related]
20. The evolving pharmacotherapy of pulmonary fibrosis.
Lota HK; Wells AU
Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]